Background/objectives

Diabetic subjects are at increased risk of subtle cognitive impairment since the disease early stages and of dementia later in life. In animal models, glucagon-like peptide-1 receptor agonizts (GLP1-RAs) have been shown to exert neuroprotective effects, expecially in the memory domain. We assessed whether treatment with a GLP1-RA might affect cognitive functions in type 2 diabetic subjects independently on the weight loss it might induce.

Subjects/methods

Forty metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes mellitus, received liraglutide (1.8 mg/d) (n = 20) or lifestyle counseling (dietary intervention and exercise training) (n = 20) until achieving a modest and comparable weight loss (−7% of initial body weight).

Interventions/methods

A detailed neuropsychological assessment before and after weight loss was completed in 16 patients per arm, who were administered a total of seven psychological tests, thus assessing three composite domain z-scores for attention, memory, and executive control.

Results

After comparable weight loss and superimposable glycemic control and insulin sensitivity, a significant increase in short term memory (mean Digit Span Z score from −0.06 to 0.80, p = 0.024) and memory composite z-score (mean memory z-score from −0.67 to 0.032, p = 0.0065) was observed in the liraglutide exposed subjects (between group p = 0.041 and p = 0.033, respectively).

Conclusions

Liraglutide might slow down memory function decline in diabetic patients in early, and possibly preclinical stages of the disease.

中文翻译：

---

利拉鲁肽可改善前驱糖尿病或早期 2 型糖尿病肥胖患者的记忆力：一项随机对照研究

背景/目标

自疾病早期阶段以来，糖尿病受试者发生轻微认知障碍和晚年痴呆的风险增加。在动物模型中，胰高血糖素样肽 1 受体激动剂 (GLP1-RAs) 已被证明具有神经保护作用，特别是在记忆领域。我们评估了 GLP1-RA 治疗是否会影响 2 型糖尿病受试者的认知功能，而与它可能引起的体重减轻无关。

科目/方法

40 名二甲双胍治疗的肥胖受试者患有前驱糖尿病或新诊断的 2 型糖尿病，接受利拉鲁肽（1.8 mg/d）（n  = 20）或生活方式咨询（饮食干预和运动训练）（n  = 20），直到达到适度和可比较体重减轻（初始体重的-7%）。

干预/方法

每组 16 名患者在减肥前后完成了详细的神经心理学评估，他们总共进行了七次心理测试，从而评估了注意力、记忆力和执行控制的三个复合域z分数。

结果

在相当的体重减轻和可叠加的血糖控制和胰岛素敏感性之后，短期记忆（平均数字跨度Z得分从 -0.06 到 0.80，p  = 0.024）和记忆复合z得分显着增加（平均记忆z得分从 -0.67在利拉鲁肽暴露的受试者中观察到 0.032，p  = 0.0065）（分别在组p  = 0.041 和p  = 0.033 之间）。

结论

利拉鲁肽可能会减缓糖尿病患者在疾病早期和临床前阶段的记忆功能下降。